Pancreatic Cancer
Conditions
Keywords
pancreatic cancer, pancreas cancer, pancreas
Brief summary
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.
Detailed description
This study administers 50.4 Gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug, Bevacizumab. The drug is an antiangiogenic agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy.
Interventions
DRUGBevacizumab
Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
DRUGCapecitabine
650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
RADIATIONRadiotherapy
Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
Sponsors
Genentech, Inc.
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Cytology or histologic proof of adenocarcinoma of the pancreatic head, body or tail prior to treatment. * Patients with nonmetastatic, unresectable, disease are eligible. * Patients with regional nodal disease are eligible. * Karnofsky performance status \>/=70. * No upper age restriction. * Absolute granulocyte count \>1,500 cells/mm3 and platelet count at least 100,000 cells/mm3. * Serum bilirubin less than 5mg/dl prior to the start of therapy with adequate biliary decompression. * Adequate bilateral renal function. * Serum creatinine \<1.5 mg/dl. * Adequate liver function; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)\</=5 times upper limit of normal. * Sexually active men must practice contraception during study. * Patients must sign study-specific consent form.
Exclusion criteria
* History or evidence upon physical examination of CNS disease. * Active infection requiring parenteral antibiotics on Day 0. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study. * Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic agent. * Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medications. * Pregnancy or lactation. * Proteinuria at baseline or impairment of renal function. * Serious, nonhealing wound, ulcer, or bone fracture. * Evidence of bleeding diathesis or coagulopathy * Clinically significant cardiovascular disease, congestive heart failure, serous cardiac arrhythmia requiring medication, or significant peripheral vascular disease within 1 year prior to Day 0. * History of aneurysms, strokes, transient ischemic attacks, and arteriovenous malformations. * Serous concomitant medical or psychiatric disorders. * Cohort receiving Capecitabine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of combination Radiation, Bevacizumab, and Capecitabine. | 6 weeks after the completion of therapy |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate tumor hypoxia via PET scanning (gallium PET with the novel hypoxia tracer Ga-68 ECMN) before, during, and after therapy. | 6 weeks after the completion of therapy. |
| To evaluate quality of life in patients receiving this therapy. | 6 weeks after the completion of therapy. |
| To evaluate the local tumor response and median survival in patients treated with the above regimen. | 6 weeks after the completion of therapy. |
| To evaluate VEGF serum levels before and after anti-VEGF therapy. | 6 weeks after the completion of therapy. |
Countries
United States
Outcome results
None listed